10 results match your criteria: "University Hospital Halle (Saale) of the Martin Luther University Halle Wittenberg[Affiliation]"
Incidence, treatment techniques, and results of distal humeral coronal shear fractures in children and adolescents-a multicenter study of the German Section of Pediatric Traumatology (SKT).
Eur J Trauma Emerg Surg
December 2024
Department of Pediatric Traumatology and Surgery, University Hospital Halle (Saale) of the Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
Purpose: Distal humeral coronal shear fractures (CSF) are uncommon and may be challenging to treat due to their size, location, and intraarticular nature. The purpose of this study was to analyze treatment concepts of this rare entity in the growing age.
Methods: Based on a multi-center data analysis we retrospectively reviewed patients below 16 years of age with CSF treated at 13 high-volume pediatric trauma centers.
Biomarkers of Aging: From Cellular Senescence to Age-Associated Diseases.
Oxid Med Cell Longev
January 2019
Heart Centre of the University Hospital Halle (Saale) of the Martin-Luther-University Halle-Wittenberg, 06120 Halle (Saale), Germany.
Assessing inflammageing.
Curr Opin Clin Nutr Metab Care
September 2017
aCharité - Universitätsmedizin Berlin and Protestant Geriatric Centre Berlin, BerlinbDepartment of Medicine III, University Hospital Halle (Saale) of the Martin-Luther University Halle-Wittenberg, HallecGerman Institute of Human Nutrition (DIfE) Potsdam-Rehbrücke, Section Physiology of Energy Metabolism, Potsdam-Rehbrücke, Germany.
Purpose Of Review: Immunosenescence has been scrutinized in detail, and evidence that inflammation and ageing are interrelated is consistent. Still, a gold standard for assessing the biological age of the immune function in an individual patient is lacking, so that immunosenescence is still not a quantifiable criterion in clinical decision-making processes.
Recent Findings: This review highlights recent (partly ongoing) studies into biomarkers of inflammation to assess immunosenescence, including large-scale studies, and quotes expert opinion statements.
IABP plus ECMO-Is one and one more than two?
J Thorac Dis
April 2017
Department of Medicine III, University Hospital Halle (Saale) of the Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
The ICM research agenda on extracorporeal life support.
Intensive Care Med
September 2017
Réanimation des Détresses Respiratoires et Infections Sévères, CHU Nord, UMR CNRS 7278, Aix-Marseille Université, Marseille, France.
Article Synopsis
- This study reviews the current standards and recent advancements in extracorporeal membrane oxygenation (ECMO), addressing misconceptions from recent trials and highlighting areas needing further research.* -
- Venovenous ECMO (VV-ECMO) is increasingly used for severe acute lung injury, while veno-arterial ECMO (VA-ECMO) offers support in cardiogenic shock; however, uncertainties regarding its benefits persist.* -
- Despite progress in ECMO applications for critically ill patients, questions about its risk/benefit ratio and effective delivery methods remain, necessitating ongoing and future research to address these challenges.*
Extracorporeal life support during cardiac arrest and cardiogenic shock-how good is the evidence really?
Ann Transl Med
February 2017
Department of Medicine III, University Hospital Halle (Saale) of the Martin-Luther University Halle-Wittenberg, Halle (Saale), Germany.
Effect of inflammatory mediators on cardiovascular function.
Curr Opin Crit Care
October 2016
aChair of Geriatrics, Charité - Universitätsmedizin Berlin and Protestant Geriatric Centre Berlin, BerlinbDepartment of Medicine I, Carl-von-Basedow Hospital Merseburg, MerseburgcDepartment of Medicine III, University Hospital Halle (Saale) of the Martin-Luther University Halle-Wittenberg, Halle (Saale), Germany.
Purpose Of Review: Inflammatory mediators can interfere with cardiovascular system. This article describes some recent findings in this field.
Recent Findings: In septic cardiomyopathy, direct and indirect interactions of endotoxin with the pacemaker current contribute to cardiac autonomic dysfunction and inadequately high heart rate, worsening prognosis.
DKG statement on the use of metal alloy discs for patch testing in suspected intolerance to metal implants.
J Dtsch Dermatol Ges
October 2015
Department of Dermatology, University Hospital Erlangen, Friedrich- Alexander University Erlangen, Germany.
Intolerance reactions to metal implants may be caused by metal allergy. However, prior to implantation, 'prophetic'/prophylactic patch testing should not be performed. Pre-implant patch testing should only be done to verify or exclude metal allergy in patients with a corresponding history.
View Article and Find Full Text PDFPantoea agglomerans - an underestimated pathogenic agent in penetrating trauma involving vegetative material.
J Eur Acad Dermatol Venereol
June 2016
Department of Dermatology and Venereology Halle (Saale), University Hospital Halle (Saale) of the Martin Luther University Halle Wittenberg, Ernst-Grube-Straße 40, Halle (Saale), Germany.
Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study.
Clin Res Cardiol
May 2012
Department of Medicine III, University Hospital Halle (Saale) of the Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
Aim: Several clinical trials have demonstrated the antianginal and anti-ischemic efficacy of ivabradine in combination with beta-blocker in patients with stable angina pectoris. The ADDITIONS (PrActical Daily efficacy anD safety of Procoralan(®) In combinaTION with betablockerS) study evaluated the efficacy, safety, and tolerability of ivabradine added to beta-blocker, and its effect on angina symptoms and quality of life in routine clinical practice.
Methods: This non-interventional, multicenter, prospective study included 2,330 patients with stable angina pectoris treated with a flexible dose of ivabradine twice daily in addition to beta-blocker for 4 months.